Keystone Lab

Keystone Bio is a clinical-stage biotechnology company focused on the oral-systemic connection, specifically targeting the toxic proteome of the bacterium Porphyromonas gingivalis. The company's lead candidate, KB-001, is a monoclonal antibody designed to neutralize gingipains, which are toxic proteases that enter the bloodstream and drive chronic inflammation and disease in the brain, heart, and other organs. Keystone Bio's approach aims to treat and prevent major systemic conditions such as Alzheimer's disease and cardiovascular disease by addressing their root cause in the oral cavity. The company is currently advancing its lead program through clinical trials while expanding its pipeline to include small molecule and vaccine candidates.